NeoStem To Present At Noble Capital Markets' Life Sciences Exposition On September 24

NEW YORK, Sept. 19, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), a rapidly emerging market leader in the fast growing cell therapy market, today announced that Company management has been invited to participate at BIOX, the Noble Financial Capital Markets' Life Sciences Exposition on Monday, September 24. Company management will make a webcasted company presentation and participate in a cell therapy panel.

Noble Financial Capital Markets Investor Conference - BIOX Life Sciences Exposition

• Company Presentation 
• Date: September 24, 2012, 9:00 AM EDT  
• Venue: University of Connecticut, Stamford, CT  
• Presenter: Robin L. Smith, M.D., M.B.A., Chairman and CEO of NeoStem  
• This presentation will be webcast only and the live webcast and 90 day archive of this presentation will be available at http://noble.mediasite.com/mediasite/Play/692761bd8fb94b7e95f0b488fa1211d01d

• Panel Presentation: Advancements in Cell Therapy & Regenerative Medicine  
• Date: September 24, 2012, 11:45 AM EDT  
• Venue: University of Connecticut, Stamford, CT  
• Room: Main meeting hall  
• Panelist: Jonathan Sackner-Bernstein, M.D., FACC, Vice President, Clinical Development and Regulatory Affairs of NeoStem

For more information about the conference, please visit www.nobleresearch.com/BIOX.htm .

About NeoStem, Inc.

NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy market. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT"), with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company.

1 2 Next › Last »